These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33026900)

  • 1. Does Pharmaceutical Compounding of Vascular Endothelial Growth Factor Inhibitors for Intravitreal Use Alter the Risk of Post-injection Endophthalmitis?
    Blom K; Bragadóttir R; Sivertsen MS; Moe MC; Jørstad ØK
    Ocul Immunol Inflamm; 2022 Apr; 30(3):713-716. PubMed ID: 33026900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review.
    Uzzan J; Mapani A; Cox O; Bagijn M; Saffar I
    Ophthalmol Ther; 2024 Sep; 13(9):2445-2465. PubMed ID: 39066961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Syringe-Filling Technique on the Risk for Endophthalmitis after Intravitreal Injection of Anti-VEGF Agents.
    Finkelstein M; Katz G; Zur D; Rubowitz A; Moisseiev E
    Ophthalmologica; 2022; 245(1):34-40. PubMed ID: 34348344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of compounded bevacizumab with postinjection endophthalmitis.
    VanderBeek BL; Bonaffini SG; Ma L
    JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
    Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C
    JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 10. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA; Knickelbein JE; Doft BH; Balasubramani GK; Wisniewski S
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections: A multicentric study.
    Sen S; Mishra C; Kannan NB; Ramasamy K; Rameshkumar G; Lalitha P
    Semin Ophthalmol; 2021 Aug; 36(5-6):413-422. PubMed ID: 33750261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    ; Patel SN; Tang PH; Storey PP; Wolfe JD; Fein J; Shah SP; Chen E; Abbey A; Ferrone PJ; Shah CP; Liang MC; Stem MS; Ali Khan M; Yonekawa Y; Garg SJ
    Ophthalmology; 2021 Nov; 128(11):1620-1626. PubMed ID: 34019955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endophthalmitis following same-day bilateral anti-VEGF injections: a systematic review.
    Bjerager J; Hajari J; Klefter ON; Subhi Y; Schneider M
    Int Ophthalmol; 2024 Feb; 44(1):37. PubMed ID: 38332399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
    Ng DS; Kwok AK; Chan CW; Li WW
    Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Legal obligation in the general population: face mask influence on endophthalmitis after intravitreal injection.
    Neubauer J; Gklavas K; Kortüm F; Gosheva M; Bartz-Schmidt KU; Ziemssen F
    Graefes Arch Clin Exp Ophthalmol; 2023 Jan; 261(1):97-102. PubMed ID: 35932321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes.
    Lode HE; Gjølberg TT; Foss S; Sivertsen MS; Brustugun J; Andersson Y; Jørstad ØK; Moe MC; Andersen JT
    Sci Rep; 2019 Dec; 9(1):18021. PubMed ID: 31792234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endophthalmitis after Anti-VEGF Intravitreal Injections with Aqueous Chlorhexidine versus Povidone-Iodine as Ocular Antiseptics.
    Ton NS; Goncharov V; Zapata I; Adam MK
    Ophthalmol Retina; 2024 Jun; 8(6):521-526. PubMed ID: 38122867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
    Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
    Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.